Salute e Benessere

Michele Pedrocchi Appointed Chair of Kinomica

Tim Fell, Chief Executive Officer of Kinomica, said: "As an international executive who has brought ground-breaking diagnostic solutions into routine clinical practice, Michele's experience and guidance will be invaluable as Kinomica seeks to do the same with phosphoproteomic diagnostics for therapy selection." Tim Fell, Chief Executive Officer of Kinomica, said : "As an international executive who has brought ground-breaking diagnostic solutions into routine clinical practice…
PR Newswire
14/01/2025

ScienceSoft Positioned as the Leader in the 2024 SPARK Matrix™: Healthcare IT…

ScienceSoft was chosen as a leader in the 2024 SPARK Matrix™: Healthcare IT Services due to its comprehensive service offering in Healthcare IT. ScienceSoftwas chosen as a leader in the 2024SPARK Matrix ™ : Healthcare IT Services due to its comprehensive service offering in Healthcare IT. QKS Group defines Healthcare IT services as a comprehensive set of digital solutions aimed at modernizing healthcare delivery by integrating technology across clinical, administrative, and operational...
PR Newswire
14/01/2025

BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan…

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a next-generation immuno-oncology (“IO”) backbone for the Company's combination strategy targeting a broad range of indicationsProgressing development of BNT327/PM8002 with initiation of global clinical trials with registrational potential in first-line small cell lung cancer (“SCLC”) and non-small...
Nasdaq GlobeNewswire
14/01/2025

LUMA Vision Successfully Completes First-in-Human Procedures with its Novel…

The first procedures, performed at the Mater Private Network, Dublin under the guidance of leading Electrophysiologist Professor Gabor Széplaki, demonstrated the VERAFEYE™ systems potential to improve procedural workflows by enhancing accuracy, visualization, and control. Professor Széplaki commented on the significance of this achievement: "The VERAFEYE™ system provides a level of detail and real-time spatial context that is unmatched by traditional imaging methods. This innovative…
PR Newswire
14/01/2025

Enea TECH and Biomedical Foundation invests €15 million in Tethis to develop new…

This platform makes it possible to characterize both immune cells and any circulating tumor cells, and to integrate cellular analysis with molecular markers present in plasma. The goal is to support accurate tumor diagnosis, monitor disease during and after treatment, and hopefully detect tumors early. This platform makes it possible to characterize both immune cells and any circulating tumor cells, and to integrate cellular analysis with molecular markers present in plasma. The goal is to...
PR Newswire
14/01/2025

Clarivate Launches DRG Fusion - A New Life Sciences Analytics Product Powered by…

Biopharma and medtech organizations face increasing challenges in extracting insights from fragmented data sources while adapting to competitive pressures and shifting market demands. Fusion addresses these issues by delivering market data and analytics from integrated medical and pharmacy claims and other real-world data sources, empowering life science organizations to create a healthier tomorrow. Its user-tested workflows and on-going data refreshes empower teams to quickly identify gaps in…
PR Newswire
14/01/2025

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd…

MEDIA RELEASE Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilarsLeading in home market Europe, which represents half of total sales; strategically positioning company to become #1 in biosimilars in US, with three US launches expected in 2025Ambitious GLP-1 strategy in place, addressing each opportunity with mix of internal capabilities and external partnershipsIndustry-leading...
Nasdaq GlobeNewswire
14/01/2025

Santhera Receives Positive Recommendation from Scottish Medicines Consortium for…

Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland AGAMREE® is approved by MHRA for treating Duchenne muscular dystrophy (DMD) in patients 4 years of age and older in UK Pratteln, Switzerland, January 14, 2025 – Santhera Pharmaceuticals (SIX: SANN) announcesthat the Scottish Medicines Consortium (SMC) has published recommendations that AGAMREE® (vamorolone) is...
Nasdaq GlobeNewswire
14/01/2025

Idorsia publishes an invitation to a bondholder meeting

Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on February 25, 2025, to vote on proposals to amend the terms of the outstanding convertible bonds maturing on January 17, 2025, including an extension of the maturity by at least six monthsAllschwil, Switzerland – January 14, 2025Idorsia Ltd (SIX: IDIA) today announced that it has published an invitation to a bondholder meeting for holders of its outstanding convertible bond (ISIN: CH0426820350) (the...
Nasdaq GlobeNewswire
14/01/2025

Ando Foundation and Nissin Food Products Release "Nourishing Wellbeing" Report…

"Making it clear that food satisfaction is an important indicator of improving wellbeing" "Making it clear that food satisfaction is an important indicator of improving wellbeing" The latest study showed that people who were completely satisfied were 1.71 times more likely than those who were not to be experiencing wellbeing, and reiterated that food, like income, was an essential component of wellbeing. The connection between satisfaction with food and four societal…
PR Newswire
14/01/2025

Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development…

Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney DiseaseA meta-analysis of VIVIAD and VIVA-MIND 1data confirmed that treatment with varoglutamstat at 600mg twice daily significantly improved eGFR 2kidney function in the overall study populationThe meta-analysis also confirmed a substantially larger effect size in study participants with diabetes 3compared to those without diabetes Vivoryon further...
Nasdaq GlobeNewswire
14/01/2025

FDA accepts Biologics License Application for subcutaneous maintenance dosing of…

The SC-AI is expected to be simple and easy for patients and their care partners to use, and may reduce the need for hospital or infusion site visits and nursing care for IV administration, which will make it easier to continue maintenance administration and may contribute to further simplifying the treatment pathway for AD. The SC-AI is expected to be simple and easy for patients and their care partners to use, and may reduce the need for hospital or infusion site visits and nursing care for...
PR Newswire
14/01/2025

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for…

LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option TOKYO and CAMBRIDGE, Mass., Jan.13, 2025(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration (FDA) has accepted...
Nasdaq GlobeNewswire
14/01/2025

Exosome Therapies Market Poised for Explosive Growth During the Study Period…

Key Takeaways from the Exosome Therapies Market Report Key Takeaways from the Exosome Therapies Market Report Discover which therapies are expected to grab the exosome therapies market share @ Exosome Therapies Market Report Exosome Therapies Market Dynamics The exosome therapy market is emerging as a dynamic sector within the biopharmaceutical industry, driven by significant advancements in understanding the role of exosomes in intercellular communication and their therapeutic potential...
PR Newswire
13/01/2025

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et…

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 13, 2025– GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract withCrédit Industriel et Commercial.Under the liquidity contract GENFIT has withCrédit Industriel et Commercial, the following resources appeared on the...
Nasdaq GlobeNewswire
13/01/2025

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF Regulated InformationChâtillon, France, January 13, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2024: ...
Nasdaq GlobeNewswire
13/01/2025

SciBase announces outcome of directed issue and preliminary outcome of rights…

Allocation of units in the Directed Issue Allocation of units in the Directed Issue All units in the Directed Issue have been subscribed and paid for, and thus, the Board of Directors of SciBase intends to resolve on the allocation of 16,669,624 units in the Directed Issue, onJanuary 14, 2025, in conjunction with the Company's resolution on allocation based on the final outcome in the Rights Issue. Each unit in the Directed Issue consists of three (3) shares and three (3) Warrants...
PR Newswire
13/01/2025

MicroAire appoints Remco Maljers as Head of International Sales

In his new role, Remco will report directly to MicroAire's president. He will lead commercial efforts outside the United States, oversee international sales strategy, strengthen relationships with our global partners, and identify new growth opportunities in emerging markets. His leadership will be instrumental in realizing MicroAire's vision to expand its global footprint and bring innovative solutions to more patients worldwide. In his new role, Remco will report directly to MicroAire's…
PR Newswire
13/01/2025

Aignostics Announces Results for Pathology Foundation Model Developed in…

"These results represent an exciting achievement in our collaboration with Mayo Clinic," said Maximilian Alber, CTO of Aignostics. "Aignostics and Mayo Clinic have direct access to millions of additional training images and new data modalities that will be integrated into the model over time, further enhancing its capabilities and accuracy." "These results represent an exciting achievement in our collaboration with Mayo Clinic," saidMaximilian Alber, CTO of…
PR Newswire
13/01/2025

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development…

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer NANTES, France, January 13, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the appointment of Dr. Sonya Montgomery as Chief Development Officer. Sonya will serve on the OSE Immunotherapeutics Executive Committee in a strategic move that will enhance the company's development capabilities. Dr. Montgomerybrings over two decades of experience leading...
Nasdaq GlobeNewswire
13/01/2025

Press release: Transparency Notification from Shareholders

Transparency Notification from ShareholdersGhent, Belgium – 13 January 2025 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to the entities listed below, notifying the number of voting rights attached to the shares mentioned next to their name in the table below. Reason for...
Nasdaq GlobeNewswire
13/01/2025

Transactions in Zealand Pharma shares and/or related securities by persons…

Company announcement – No. 1 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, January 13, 2025–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or...
Nasdaq GlobeNewswire
13/01/2025

Yoga Straps Market Analysis: Key Trends in 8-Foot and 6-Foot Straps | Online…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-32U6902/Global_Yoga_Straps_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-32U6902/Global_Yoga_Straps_Market Major Factors Driving the Growth of Yoga Straps Market: The Yoga Straps market is poised for substantial growth, driven by the increasing global participation in yoga practices and the rising demand for supportive yoga accessories. Yoga straps enhance the...
PR Newswire
13/01/2025

Spatial Genomics & Transcriptomics Market to Hit USD 995.7 Million by 2029 with…

Browse in-depth TOC on "Spatial Genomics & Transcriptomics Market" Browse in-depth TOC on "Spatial Genomics & Transcriptomics Market" 613 - Tables 65 - Figures 451 - Pages Based on Offerings,the market is divided into products and services segments. In 2023, the product segment accounted for the highest share of the spatial genomics and transcriptomics market. The growing demand for high-resolution spatial gene and protein expression data in research is mostly...
PR Newswire
13/01/2025
Altri  Comunicati